Interesting that RES, LL, and the GLP-1 class are all now being currently being studied in the newest mouse model studies that were PR’ed last week - three months after the authors ended their paper with this paragraph:

As the “multi-hit hypothesis” holds, combining the therapeutic approaches of GLP-1 agonists with resmetirom seems like a promising strategy by targeting the multifaceted pathophysiology of MASH, which may lead to improved patient outcomes. While the “synergy” makes sense, it is still theoretical until proven in dedicated trials or, suboptimally, from data in real-world studies.